Core Viewpoint - The company, Kexing Pharmaceutical, is actively pursuing funding to support its new drug development and international commercialization efforts, indicating a strategic focus on growth in the biopharmaceutical sector [1] Company Overview - Kexing Pharmaceutical's latest stock price is 44.63 yuan, reflecting a 0.56% increase from the previous trading day [1] - The stock reached a high of 44.91 yuan and a low of 43.26 yuan during the trading session, with a total transaction volume of 314 million yuan and a turnover rate of 3.53% [1] - The company specializes in the research, development, production, and sales of recombinant protein drugs and microbiome preparations, with key products including recombinant human erythropoietin, recombinant human interferon α1b, and Clostridium butyricum dual live bacteria [1] Financial Activities - The company plans to apply for the registration of technology innovation bonds not exceeding 800 million yuan to support new drug research and overseas commercialization [1] - The board has approved a resolution to provide interest-free loans of up to 20 million yuan to its wholly-owned subsidiary, specifically for the upgrade of the research and development center [1] Capital Flow - On the day of reporting, the net outflow of main funds was 6.722 million yuan, with a cumulative net outflow of 78.8172 million yuan over the past five trading days [1]

Core Points - Company announced the convening of the 28th meeting of the second board and the 24th meeting of the second supervisory board on August 14, 2025 [2] - The board approved a proposal to provide interest-free loans to its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical, using part of the raised funds [2] - The total amount of the interest-free loan will not exceed 20 million yuan, aimed at advancing the construction and implementation of the fundraising project [2] - The loan term is set for three years from the actual borrowing date, with provisions for renewal or early repayment subject to the general manager's approval [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the approval of several proposals, including the use of part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects [2] Group 2 - The announcement was made during the 28th meeting of the second board of directors [2] - The decision reflects the company's strategy to support its subsidiary in executing investment projects [2] - The funding mechanism involves utilizing raised capital, indicating a focus on internal resource allocation for growth [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the approval of several proposals, including the use of part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects [2] Group 2 - The second meeting of the second supervisory board of Kexing Pharmaceutical took place on August 15, where multiple proposals were reviewed and approved [2] - The specific proposal involves using part of the raised funds to support the subsidiary's projects, indicating a strategic move to enhance operational capabilities [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the convening of its 28th board meeting on August 14, 2025, to discuss various proposals, including the establishment of certain systems [1] - For the year 2024, Kexing Pharmaceutical's revenue composition is as follows: 99.59% from pharmaceutical manufacturing, 0.25% from other businesses, and 0.16% from other sources [1] - As of the report date, Kexing Pharmaceutical has a market capitalization of 9 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing scrutiny over an 11 billion yuan acquisition, as the major client of the acquisition target has been in a debt crisis for two years, raising questions about its ability to contribute significant revenue [1]

Meeting Overview - The second meeting of the second supervisory board of the company was held on August 14, 2025, with all three supervisors present [1]. Resolutions Passed Use of Raised Funds - The supervisory board approved the proposal to provide interest-free loans from raised funds to the wholly-owned subsidiary Shenzhen Kexing Pharmaceutical for project implementation, aligning with the fundraising plan and benefiting project execution [1]. Foreign Exchange Derivative Transactions - The board approved the proposal for the company and its subsidiaries to engage in foreign exchange derivative transactions, with a limit of 75 million RMB or equivalent foreign currency, to mitigate foreign exchange risk and enhance financial stability [2]. Related Party Transaction Agreement - The board approved the signing of a supplementary agreement for related party transactions, confirming compliance with regulations and ensuring no adverse effects on the company's financial status or shareholder interests [2]. Issuance of Technology Innovation Bonds - The board approved the proposal for the company to issue technology innovation bonds, affirming that it aligns with the overall interests of the company and shareholders [3].

是否需要提交股东大会审议：否 对上市公司的影响：科兴生物制药股份有限公司（以下简称"公司"）全 资子公司与关联方签署关联交易补充协议是为了满足子公司日常业务发展需要， 为正常的持续性合作。公司关联交易符合相关法律、法规的规定，关联交易的定 价主要遵循市场价格和公开、公平、公正及合理的原则，没有损害公司及股东的 利益，不会对公司的独立性产生影响，也不会对关联方形成较大的依赖。 一、日常关联交易基本情况 （一）关联交易概述 公司全资子公司深圳科兴药业有限公司（以下简称"深圳科兴"）向正中产 业控股集团有限公司（以下简称"正中产控"）租赁房产，作为深圳科兴日常经 营使用，双方于 2018 年 8 月 30 日签署《房屋租赁合同》（以下简称"原租赁协 议"），租赁期限自 2018 年 9 月 1 日至 2028 年 12 月 31 日。 证券代码：688136 证券简称：科兴制药 公告编号：2025-063 科兴生物制药股份有限公司 关于签署关联交易协议补充协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ...

为有效防范汇率大幅波动对公司经营业绩造成不利影响，提高外汇资金 使用效率，科兴生物制药股份有限公司（以下简称"公司"）及合并报表范围内 子公司拟使用自有资金开展总金额不超过7,500万元人民币或等值外币的外汇衍 生品交易，包括但不限于远期结售汇、人民币和其他外汇的掉期、外汇期权、利 率互换、利率掉期、利率期权等。公司及控股子公司开展外汇衍生品交易业务的 交易对手为具有外汇衍生品交易业务经营资格、经营稳健且资信良好的金融机构。 上述交易额度的使用期限自公司董事会审议通过之日起至2025年12月31日，有效 期内可以滚动使用，但在授权使用有效期内任一时点的金额不应超过审议额度。 公司于2025年8月14日召开第二届董事会第二十八次会议，审议通过了 《关于开展2025年度外汇衍生品交易业务的议案》，该议案无需提交公司股东会 审议。本项业务不构成关联交易。 特别风险提示：公司开展外汇衍生品交易业务遵循合法、谨慎、安全和 有效的原则，不进行单纯以盈利为目的的投机和套利交易，但外汇衍生品交易业 务仍存在包括但不限于市场风险、流动性风险、内部控制风险和履约风险等，敬 请广大投资者注意投资风险。 一、交易情况概述 证券代码： ...

科兴生物制药股份有限公司 关于开展外汇衍生品交易业务的可行性分析报告 一、公司开展外汇衍生品交易业务的背景 在外汇环境不稳定、汇率波动较为频繁的背景下，为有效防范和规避外币汇率波动可能 带来的不利影响，提高应对外汇波动风险的能力，促进财务稳健性，公司及子公司拟使用自 有资金开展外汇衍生品交易业务。 公司及子公司结合实际业务情况适度开展外汇衍生品交易业务具备必要性和可行性，能 在一定程度上防范和规避外汇市场波动有可能带来的风险，有利于进一步增强财务稳健性， 符合公司实际发展需要。 二、公司开展外汇衍生品交易业务的基本情况 （一）交易品种与对手 公司及子公司将按照衍生品套保原则和汇率风险中性管理原则，根据合同需要灵活选择 外汇远期、外汇期权、外汇掉期等结构相对简单透明、流动性强、风险可认知、市场有公开 参考价格、不超过 12 个月的外汇衍生工具，不从事复杂嵌套、与不可控因素挂钩的外汇衍 生工具交易。交易对手为具有外汇衍生品交易业务经营资格、经营稳健且资信良好的国内和 国际性金融机构。 （二）交易额度、期限及授权 公司及子公司拟开展的外汇衍生品交易业务额度不超过 7,500 万元人民币或等值外币， 上述额度在审批期 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-061 科兴生物制药股份有限公司 关于使用部分募集资金向全资子公司提供无息借款 公司监事会发表了明确同意的意见，公司保荐机构中信建投证券股份有限公 司对该事项出具了明确的核查意见。 一、募集资金基本情况 以实施募投项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）于2025年8月14日召开第 二届董事会第二十八次会议和第二届监事会第二十四次会议，审议通过了《关于 使用部分募集资金向全资子公司提供无息借款以实施募投项目的议案》，同意公 司根据募集资金投资项目（以下简称"募投项目"）的建设安排及实际资金需求 情况，在不超过募投项目"研发中心升级建设项目"总投入募集资金金额的情况 下，公司本次拟使用募集资金向全资子公司深圳科兴药业有限公司（以下简称"深 圳科兴药业"）提供总额不超过2,000万元的无息借款，专项用于推进募投项目 的建设和实施，并授权公司管理层负责无息借款手续办理以及后续的管理工作。 ...